Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Non-Current Assets: 2020-2024

Historic Non-Current Assets for Mirum Pharmaceuticals (MIRM) over the last 5 years, with Dec 2024 value amounting to $278.0 million.

  • Mirum Pharmaceuticals' Non-Current Assets fell 9.50% to $254.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $254.5 million, marking a year-over-year decrease of 9.50%. This contributed to the annual value of $278.0 million for FY2024, which is 7.29% up from last year.
  • Per Mirum Pharmaceuticals' latest filing, its Non-Current Assets stood at $278.0 million for FY2024, which was up 7.29% from $259.1 million recorded in FY2023.
  • Over the past 5 years, Mirum Pharmaceuticals' Non-Current Assets peaked at $278.0 million during FY2024, and registered a low of $4.5 million during FY2020.
  • Its 3-year average for Non-Current Assets is $233.2 million, with a median of $259.1 million in 2023.
  • Data for Mirum Pharmaceuticals' Non-Current Assets shows a peak YoY surged of 2,736.93% (in 2021) over the last 5 years.
  • Over the past 5 years, Mirum Pharmaceuticals' Non-Current Assets (Yearly) stood at $4.5 million in 2020, then spiked by 2,736.93% to $128.1 million in 2021, then rose by 27.04% to $162.7 million in 2022, then skyrocketed by 59.26% to $259.1 million in 2023, then climbed by 7.29% to $278.0 million in 2024.